Martingale Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Martingale Asset Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,520	Closed	-$155K	–	871
2024 Q1	$155K	Buy	+10,520	New	+$148K	﹤0.01%	793

Other funds holding MACK

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Martingale Asset Management's MACK Position: Q2 2024 in Review

Martingale Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 10,520 shares — an estimated $155K sold.

Martingale Asset Management first reported a position in MACK in Q1 2024 and held it in 1 quarter. The position peaked at $155K in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

Martingale Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Martingale Asset Management sold 10,520 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $155K.
Martingale Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2024 and held it in 1 quarter.
Martingale Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $155K in Q1 2024.
12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Martingale Asset Management's 13F filing for Q2 2024, filed 12 Aug 2024.